DUPIXENT is not used to relieve sudden breathing problems and will not replace an inhaled rescue medicine. have eye problems. have a parasitic (helminth) infection. are scheduled to receive any ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Sanofi stock forms a Golden Cross, signaling bullish momentum as Dupixent nears FDA approval for bullous pemphigoid. SNY’s technicals remain strong, with all key moving averages trending higher ...

Dupixent may become the first targeted treatment for bullous pemphigoid in the U.S., pending FDA approval by June 2025. Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...

DUPIXENT is not used to relieve sudden breathing problems and will not replace an inhaled rescue medicine. have eye problems. have a parasitic (helminth) infection. are scheduled to receive any ...